Prostate cancer
Finding the right ADT for the right patient
For more than 8 decades, ADT has been playing an important role in advanced prostate cancer (PCa) treatment. Nevertheless, understanding and optimising this therapy is still challenging. With different ADT options varying in administration route and adverse event profiles, healthcare providers are challenged with choosing the most optimal treatment for specific patient populations. In addition, great differences exist among the patients’ personal preferences regarding the treatment choice. This should be taken into account during shared decision-making and personalisation of the ADT, together with maximising benefit and minimising harm to the patients.